期刊文献+

替米沙坦联合吡格列酮干预糖尿病肾病大鼠蛋白尿发生的机制 被引量:3

Mechanism of proteinuria prevention by combination of telmisartan and pioglitazone in diabetic nephropathy rats
原文传递
导出
摘要 目的观察替米沙坦联合吡格列酮对糖尿病肾病(DN)大鼠肾小球基底膜乙酰肝素酶(HPA)和足细胞podocin表达的影响,并探讨其可能机制。方法构建DN大鼠动物模型,将大鼠随机分为替米沙坦组(T组)、吡咯列酮组(B组)、替米沙坦+吡格列酮联合组(L组)、DN组(D组)及健康对照组(N组)。12周后检测尿蛋白量(24h)及血生化指标,用RT—PCR和免疫组化检测HPA、podocinmRNA和蛋白的表达。结果灌胃12周后,L组尿蛋白量(24h)显著低于T组、B组,差异有统计学意义(P〈0.05)。与N组相比,T组、B组、L组、D组空腹血糖、相对肾质量、BUN、Scr均较高,差异有统计学意义(均P〈0.05)。L组的Scr显著低于T组、B组,差异具有统计学意义(均P〈0.05)。与N组相比,其余4组HPA蛋白表达较高,L组显著低于T组、B组;但其他4组podocin蛋白表达水平较低,L组显著高于T组、B组,差异均有统计学意义(均P〈0.05)。与N组相比,其他4组HPA和podocinmRNA表达量较高,L组HPAmRNA表达显著低于T组、B组,podocinmRNA表达显著高于T组、B组,差异均有统计学意义(均P〈0.05)。结论替米沙坦联合吡格列酮较单用药显著减轻DN大鼠早期蛋白尿,此作用可能通过下调DN肾小球基底膜HPA,上调足细胞podocin蛋白的表达实现。 Objective To study the combination effects of telmisartan and pioglitazone on the expression of heparanases (HPA) and podocin in the kidney of diabetic nephropathy (DN) rats and its possible mechanism. Methods DN model rats were established by intraperitoneal injection with STZ for 12 weeks. All the DN rats were randomly divided into telmisartan group (T group), pioglitazone group (P group), combination of telmisartan and pioglitazone group (L group), and DN group (D group). Healthy rats were chosen as healthy control group(N group). After garage with drugs for 12 weeks, 24-h urinary protein and serum biochemical indicators were examined. RT-PCR and immunohistochemistry methods were applied to detect the mRNA and protein expression of HPA and podocin. Results Compared with T group and P group, 24-b urinary protein of L group was markedly decreased(P〈0.05). Compared with the N group, the level of fasting blood glucose, relative renal weight, BUN and Scr in other 4 groups were markedly increased (P〈0.05). Compared with T group and P group, the Scr level and the expression of HPA mRNA and protein in L group was markedly decreased (P〈0.05), and the protein and mRNA expression of podocin in L group was markedly increased (P〈0.05). Conclusion Combination of telmisartan and pioglitazone can down-regulate the mRNA and protein expression of HPA of glomerular basement membrane and up-regulate the protein expression of podocin of podocyte in DN rats, which may ameliorate the proteinuria.
出处 《中华肾脏病杂志》 CAS CSCD 北大核心 2008年第11期810-814,共5页 Chinese Journal of Nephrology
基金 河南省科技厅普通攻关项目(624420033)
关键词 糖尿病肾病 蛋白尿 替米沙坦 吡格列酮 Diabetic nephropathy Proteinuria Telmisartan Pioglitazone
  • 相关文献

参考文献15

  • 1Raats CJ, van den Born J, Berden JH. Glomerular heparan sulfate ahernations: mechanisms and relevance for proteinuria. Kidney Int, 2000, 57: 385-400.
  • 2Koop K, Eikmans M, Baelde HJ, et al. Expression of podocyte-associated molecules in acquired human kidney diseases. J Am Soc Nephrol, 2003, 14: 2063-2071.
  • 3Raila J, Forterre S, Schweigert FJ. Physiologic and pathophysiologic fundamentals of proteinuria - a review. Berl Munch Tierarztl Wochenschr, 2005, 118: 229-239.
  • 4Katz A, van Dijk DJ, Aingorn H, et al. Involvement of human heparanase in the pathogenesis of diabetic nephropathy. Isr Med Assoc J, 2002, 4: 996-1002.
  • 5王玉华,唐琳,刘章锁.乙酰肝素酶与蛋白尿性肾脏疾病的关系[J].国际移植与血液净化杂志,2007,5(4):10-15. 被引量:3
  • 6Maxhimer JB, Somenek M, Rao G, et al. Heparanase-1 gene expression and regulation by high glucose in renal epithelial cells: a potential role in the pathogenesis of proteinuria in diabetic patients. Diabetes, 2005, 54: 2172-2178.
  • 7Isshiki K, Haneda M, Koya D, et al. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes, 2000, 49: 1022-1032.
  • 8Shafat I,Zcharia E,Nisman B,et al.An ELISA method for the detection and quantification of human heparanase. Biochem Biophys Res Commun, 2006, 341: 958-963.
  • 9van Den Hoven MJ, Rops AL, Bakker MA, et al. Increased expression of heparanase in overt diabetic nephropathy. Kidney Int, 2006, 70: 2100-2108.
  • 10刘章锁,牛红心,程根阳,李军辉,宋洁.罗格列酮对糖尿病大鼠肾保护机制的研究[J].中华肾脏病杂志,2004,20(2):109-112. 被引量:35

二级参考文献27

  • 1林沁,顾勇,马骥,林善锬.罗格列酮对肾间质损伤的防护作用及其机制[J].中华医学杂志,2005,85(23):1618-1624. 被引量:9
  • 2Nicholas SB, Kawano Y, Wakino S, et al. Expression and function of peroxisome proliferators-activated receptor-γin mesangial cells.Hypertension, 2001,37 (Pt 2 ): 722.
  • 3Tsuchiya T, Shimizu H, Shimomura K, et al. Troglitazone inhibits isolated cell proliferation, and induces apoptosis in isolated rat mesangial cells. Am J Nephrol, 2003, 23: 222-228.
  • 4Asano T, Wakisaka M, Yoshinnari M, et al. Peroxisome proliferator activated receptor gamma 1 (PPARγ1) expresses in rat messeagial cells and PPARγ1 agonists modulate its differentiation.Biochim Biophys Acta, 2000; 1497 ( 1 ): 148-154.
  • 5Ricote M, Li AC, Willson TM, et al. The peroxisome proliferators-activated receptor-γ is a negative regulator of macrophage activation. Nature, 1998, 391: 79-82.
  • 6Su CG, Wen XM, Bailey ST, et al. A novel therapy for colitis utilizing PPAR ligands to inhibit the epithelial inflammatory response. J Clin Invest, 1999, 104: 383-389.
  • 7奚涛.受体的调节.见:吴梧桐,主编.现代生化药学.第1版.北京:中国医药科技出版社,2002.212-215.
  • 8Parameswaran N, Hall CS, Bomberger JM, et al. Negative growth effects of ciglitazone on kidney interstitial fibroblasts: role of PPAR-gamma. Kidney Blood Press Res, 2003; 26: 2-9.
  • 9RE Buckingham, KA A1-Barazanji, CD Toseland, et al.Peroxisome proliferator activated receptor agonist, rosiglitazone,protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes, 1998,47: 1326-1334.
  • 10Ma LJ, Marcantpni C, Linton MF, et al. Peroxisome proliferator activated receptor-γagonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int, 2001,59: 1899-1910.

共引文献48

同被引文献26

  • 1孙正达,马骥,顾勇,林善锬.吡咯列酮对单肾切除的糖尿病大鼠肾脏纤维化的作用[J].复旦学报(医学版),2003,30(3):235-238. 被引量:4
  • 2LIUBi-cheng XUYan MAKun-ling HUANGHai-quan YINLian-fang LIUDian-ge.Effects of irbesartan on the expression of matrix metalloproteinase-2/ tissue inhibitor of metalloproteinase-2 in streptozotocin-induced diabetic rat kidney[J].Chinese Medical Journal,2005(12):1040-1044. 被引量:7
  • 3Raats CJ, Van Den BJ, Berden JH. Glomerular heparan sulfate alterations: Mechanlsms and relevance for proteinuria [ J ]. Kidney Int, 2000,57 ( 2 ) : 385- 400.
  • 4Maxhimer JB,Somenek M,Rao G,et al. Heparanase-I gene expression and regulation by high glucose in renal epithelial cells : A potential role in the pathogenesis of proteinuria in diabetic patients[J]. Diabetes,2005,54 (7) :2172- 2178.
  • 5Levidiotis V, Freeman C, TikellJs C, et al. Heparannase inhibition reduces proteinuria in a model of accelerated anti-glomerular basement membrane antibody disease [ J ]. Nephrology,2006,10 (2) : 167-173.
  • 6Martens FM, Visseren FL, Lemay J, et al. Metabolic and additional vascular effects of thiazolidinediones [ J ]. Drugs ,2002,62 (10) : 1463-1480.
  • 7Wapstra FH ,Navis GJ,van Goor H,et al. ACE inhibition preserves heparan sulfate proteoglycans in the glomerular basement membrane of rats with established Adriamycin nephropathy [ J ]. Exp Nephrol,2001,9( 1 ) :21-27.
  • 8Levidiotis V, Freeman C, Punler M, et al. A synthetic heparaanse inhibitor reduces proteinuria in passive Heymann nephritis [ J ]. J Am Soc Nephrol, 2004, 15( 11 ) :2882-2892.
  • 9Levidiotis V,Freeman C,Tikellis C ,et al. Heparanase is involved in the pathogenesis of proteinuria as a result of glomerulonephritis[ J]. J Am Soc Nephtol, 2004,15( 1 ) :68-78.
  • 10Kramer A, van den HM, Rops A, et aL Induction of glomemlar heparanaae expression in rats with adriamycin nephropathy is regulated by reactive oxygen species and the renin-angiotensin system[ J ]. J Am Soc Nephrol,2006 ,17 ( 9 ) : 2513-2520.

引证文献3

二级引证文献81

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部